TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 18
1.2 MARKET SYNOPSIS 18
1.3 KEY CONTRIBUTING FACTORS 19
2 MARKET INTRODUCTION
2.1 DEFINITION 20
2.2 SCOPE OF THE STUDY 20
2.3 RESEARCH OBJECTIVE 20
2.4 MARKET STRUCTURE 21
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 22
3.2 PRIMARY RESEARCH 24
3.3 SECONDARY RESEARCH 25
3.4 MARKET SIZE ESTIMATION 25
3.5 FORECAST MODEL 27
3.6 LIST OF ASSUMPTIONS 28
4 MARKET DYNAMICS
4.1 OVERVIEW 29
4.2 DRIVERS 30
4.2.1 HIGH INCIDENCE OF OSTEOSARCOMA 30
4.2.2 RISING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH 30
4.2.3 RISING DEMAND FOR NEW TREATMENTS 30
4.3 RESTRAINTS 31
4.3.1 HIGH COST OF TREATMENT 31
4.3.2 SIDE-EFFECTS OF CHEMOTHERAPY 31
4.4 OPPORTUNITIES 32
4.4.1 ENTERING DEVELOPING ECONOMIES 32
4.5 MACROECONOMIC INDICATORS 33
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL 34
5.1.1 BARGAINING POWER OF SUPPLIERS 35
5.1.2 BARGAINING POWER OF BUYERS 35
5.1.3 THREAT OF NEW ENTRANTS 35
5.1.4 THREAT OF SUBSTITUTES 35
5.1.5 INTENSITY OF RIVALRY 35
5.2 VALUE CHAIN ANALYSIS 36
5.2.1 R&D AND DESIGNING 37
5.2.2 MANUFACTURING 37
5.2.3 DISTRIBUTION 37
5.2.4 MARKETING & SALES 37
5.2.5 POST-SALES MONITORING 37
5.3 EPIDEMIOLOGY DATA 38
5.4 CLINICAL TRIALS ANALYSIS 39
5.5 PIPELINE ANALYSIS 41
5.5.1 PEMETREXED 41
5.5.2 INHALED LIPID CISPLATIN 41
6 GLOBAL OSTEOSARCOMA MARKET, BY TYPE
6.1 OVERVIEW 42
6.2 INTRAMEDULLARY OSTEOSARCOMA 43
6.3 JUXTACORTICAL OSTEOSARCOMA 44
6.4 EXTRASKELETAL OSTEOSARCOMA 44
7 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
7.1 OVERVIEW 45
7.2 TREATMENT 46
7.2.1 CHEMOTHERAPY 47
7.2.2 SURGERY 47
7.2.3 RADIATION THERAPY 47
7.3 DIAGNOSIS 48
7.3.1 IMAGING 48
7.3.2 BIOPSIES 49
7.3.3 BLOOD TESTS 50
8 GLOBAL OSTEOSARCOMA MARKET, BY END USER
8.1 OVERVIEW 51
8.2 HOSPITALS & CLINICS 52
8.3 DIAGNOSTIC CENTERS 52
8.4 ACADEMIC & RESEARCH ORGANIZATIONS 53
9 GLOBAL OSTEOSARCOMA MARKET, BY REGION
9.1 OVERVIEW 54
9.2 AMERICAS 56
9.2.1 NORTH AMERICA 60
9.2.2 LATIN AMERICA 69
9.3 EUROPE 73
9.3.1 WESTERN EUROPE 76
9.3.2 EASTERN EUROPE 99
9.4 ASIA-PACIFIC 103
9.4.1 JAPAN 107
9.4.2 CHINA 110
9.4.3 INDIA 113
9.4.4 SOUTH KOREA 116
9.4.5 REST OF ASIA-PACIFIC 119
9.5 MIDDLE EAST & AFRICA 123
9.5.1 MIDDLE EAST 127
9.5.2 AFRICA 130
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 134
10.2 KEY DEVELOPMENTS 134
11 COMPANY PROFILES
11.1 PFIZER INC. 136
11.1.1 COMPANY OVERVIEW 136
11.1.2 FINANCIAL OVERVIEW 137
11.1.3 PRODUCTS/SERVICES OFFERED 137
11.1.4 KEY DEVELOPMENTS 138
11.1.5 SWOT ANALYSIS 138
11.1.6 KEY STRATEGIES 138
11.2 BRISTOL-MYERS SQUIBB COMPANY 139
11.2.1 COMPANY OVERVIEW 139
11.2.2 FINANCIAL OVERVIEW 139
11.2.3 PRODUCTS/SERVICES OFFERED 140
11.2.4 KEY DEVELOPMENTS 140
11.2.5 SWOT ANALYSIS 140
11.2.6 EY STRATEGIES 141
11.3 ELI LILLY AND COMPANY 142
11.3.1 COMPANY OVERVIEW 142
11.3.2 FINANCIAL OVERVIEW 143
11.3.3 PRODUCTS/SERVICES OFFERED 143
11.3.4 KEY DEVELOPMENTS 143
11.3.5 SWOT ANALYSIS 144
11.3.6 KEY STRATEGIES 144
11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 145
11.4.1 COMPANY OVERVIEW 145
11.4.2 FINANCIAL OVERVIEW 146
11.4.3 PRODUCTS/SERVICES OFFERED 146
11.4.4 KEY DEVELOPMENTS 146
11.4.5 SWOT ANALYSIS 147
11.4.6 KEY STRATEGIES 147
11.5 BAXTER INTERNATIONAL 148
11.5.1 COMPANY OVERVIEW 148
11.5.2 FINANCIAL OVERVIEW 148
11.5.3 PRODUCTS/SERVICES OFFERED 149
11.5.4 KEY DEVELOPMENTS 149
11.5.5 SWOT ANALYSIS 150
11.5.6 KEY STRATEGIES 150
11.6 NOVARTIS AG 151
11.6.1 COMPANY OVERVIEW 151
11.6.2 FINANCIAL OVERVIEW 151
11.6.3 PRODUCTS/SERVICES OFFERED 152
11.6.4 KEY DEVELOPMENTS 152
11.6.5 SWOT ANALYSIS 153
11.6.6 KEY STRATEGIES 153
11.7 AUROBINDO PHARMA LIMITED 154
11.7.1 COMPANY OVERVIEW 154
11.7.2 FINANCIAL OVERVIEW 154
11.7.3 PRODUCTS/SERVICES OFFERED 155
11.7.4 KEY DEVELOPMENTS 155
11.7.5 SWOT ANALYSIS 156
11.7.6 KEY STRATEGIES 156
11.8 HIKMA PHARMACEUTICALS PLC 157
11.8.1 COMPANY OVERVIEW 157
11.8.2 FINANCIAL OVERVIEW 157
11.8.3 PRODUCTS/SERVICES OFFERED 158
11.8.4 KEY DEVELOPMENTS 158
11.8.5 SWOT ANALYSIS 159
11.8.6 KEY STRATEGIES 159
11.9 MYLAN NV 160
11.9.1 COMPANY OVERVIEW 160
11.9.2 FINANCIAL OVERVIEW 161
11.9.3 PRODUCTS/SERVICES OFFERED 162
11.9.4 KEY DEVELOPMENTS 162
11.9.5 SWOT ANALYSIS 163
11.9.6 KEY STRATEGIES 163
11.10 ADVAXIS, INC. 164
11.10.1 COMPANY OVERVIEW 164
11.10.2 FINANCIAL OVERVIEW 164
11.10.3 PRODUCTS/SERVICES OFFERED 164
11.10.4 KEY DEVELOPMENTS 165
11.10.5 SWOT ANALYSIS 165
11.10.6 KEY STRATEGIES 166
12 APPENDIX
12.1 REFERENCES 167
12.2 RELATED REPORTS 167